Citi initiated coverage on AbbVie Inc (NYSE: ABBV) Monday with a Sell rating and $48 price target. Analyst Andrew Baum felt that the market has underestimated the "timing and magnitude" of Humira ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results